Hormonal
A single-administration self-boosting microneedle patch delivering semaglutide sustains therapeutic plasma levels and induces weight loss in rats for one month, effectively simulating four separate weekly subcutaneous injections.
This research proposes a microneedle patch that delivers semaglutide (a weight-loss drug) through the skin. Instead of getting a shot every week, you apply a small patch once, and it releases the medication slowly over four weeks. In rats, this worked just as well as getting four separate shots. While promising for reducing pain and improving adherence, this is still experimental technology tested only on animals, not yet available for human use.
Our PSR-MNs system provides an advanced injection-free platform to significantly enhance the current treatment of obesity with GLP-1RAs... A single skin administration of a PSR-MNs patch... enables the repeated release of Semaglutide every 7 days and sustains the drug efficacy for an unprecedented one-month period, simulating the effect of using four bolus injections spaced 7 days apart.
Why this rating
The study is an in vivo animal model (rats) with a small sample size (n=4 per group) and lacks long-term human clinical data.
Source
Single‐Administration Self‐Boosting Microneedle Patch for the Treatment of Obesity
Parbeen Singh et al. · Advanced Therapeutics · 2024
DOI 10.1002/adtp.202400028
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →